Results 201 to 210 of about 13,427 (242)
Some of the next articles are maybe not open access.
Regulatory Cells in Allergen-Specific Immunotherapy
Immunotherapy, 2012Allergen-specific immunotherapy (SIT) is currently the best available curative treatment in allergies and has been used for the treatment of patients for the past 100 years. The formation of a Th2 cell predominant inflammation in addition to production of allergen-specific IgE, the attraction of proinflammatory cells and the degranulation of effector ...
Soyka, M B, Holzmann, D, Akdis, C A
openaire +3 more sources
Allergen-Specific Immunotherapy (ASIT)
2019The reader can find the up-to-date information on allergens and their nomenclature, subcutaneous and sublingual methods of allergen-specific therapy (ASIT), mechanisms of action of ASIT, clinical efficacy, etc. There is an explanation why the ASIT as a modality of treatment for atopic allergic conditions is more important and be predominant in the near
openaire +1 more source
Standards for practical allergen‐specific immunotherapy
Allergy, 2006Foreword The paper was drafted by Emilio Alvarez-Cuesta (chairman), Spain, Jean Bousquet, France, G Walter Canonica, Italy, Stephen Durham, England, Hans-Jorgen Mailing, Denmark and Erkka Valovirta, Finland. The paper was revised and input added by a European Reference Group, endorsed by National Societies associated EAACI and approved by the Executive
Alvarez Cuesta E +6 more
openaire +3 more sources
Immunologic mechanisms of allergen-specific immunotherapy
2001Allergic diseases basically are immunological disorders, related to activation of a distinct cytokine pattern in T cells, including increased secretion of certain allergic inflammatory cytokines, in particular of IL-4, IL-5 and/or IL-13. (1-3).
C A, Akdis, K, Blaser
openaire +2 more sources
Allergen specific immunotherapy for atopic dermatitis
Current Opinion in Allergy & Clinical Immunology, 2007To describe recent developments as well as the pros and cons of allergen specific immunotherapy as a putative therapeutic option for a subgroup of patients with atopic dermatitis.The question whether specific immunotherapy would impair or improve the severity and course of atopic dermatitis has been a matter of debate for a long time.
openaire +2 more sources
Allergen-Specific Immunotherapy with Recombinant Allergens
2011Subcutaneous immunotherapy is a well-documented treatment of allergic rhinitis and asthma. The major limitation is the risk of anaphylactic side effects. The documentation of clinical efficacy is based on crude allergenic extracts sometimes containing varying amounts of individual allergens including allergens to which the patient may not be sensitized.
G, Pauli, Hans-Jørgen, Malling
openaire +2 more sources
Allergen-specific immunotherapy in childhood asthma
Current Opinion in Pediatrics, 1997Immunotherapy has been shown to prevent rhinitis symptoms in seasonal allergic rhinitis, and to prevent anaphylaxis to hymenoptera and fire ant stings. The evidence supporting its effectiveness in the treatment of asthma is much more limited; it appears that clinical trials, until the past year, have only tested therapy for single allergens such as ...
openaire +2 more sources
Mechanisms of allergen-specific immunotherapy
Folia Pharmacologica JaponicaAllergen-specific immunotherapy (AIT) has been a longstanding treatment for allergic diseases. Historically, subcutaneous immunotherapy was the main approach, but with the development of sublingual preparations, which are associated with fewer systemic side effects, sublingual immunotherapy is gaining global popularity.
openaire +2 more sources
Allergen-specific immunotherapy in allergic rhinitis
Current Opinion in Allergy and Clinical Immunology, 2001The scope of this review is to highlight important and interesting articles in the field of allergen-specific immunotherapy in allergic rhinitis published within the past year. The review is not intended to give a full overview of published literature but rather to focus on some subjects that I find significant in relation to the understanding of the ...
openaire +2 more sources
[Intralymphatic allergen-specific immunotherapy].
Ugeskrift for laeger, 2019An emerging method for allergen-specific immunotherapy is intralymphatic placement, which only requires three injections with intervals of four weeks. In this review, we summarise available evidence on clinical safety, biological efficacy and therapeutic outcomes. The treatment appears to be safe with only few and mild adverse reactions.
Sara Haunstrup, Næraa +3 more
openaire +1 more source